FDA approves Bristol Myers Squibb's iberdomide for relapsed/refractory multiple myeloma
The FDA nod adds a new treatment option for patients with relapsed or refractory multiple myeloma.
Oncology Nursing News · +14 outlets
AstraZeneca reports positive Phase III results for Tagrisso-Orpathys lung cancer combination extending survival
The combination therapy showed extended survival in a lung cancer trial, boosting AstraZeneca's oncology pipeline.
DirectorsTalk Interviews · +4 outlets
PTC Therapeutics wins auction for ST-920 Fabry gene therapy in deal worth up to $211M
PTC acquired the gene therapy candidate for Fabry disease through a bankruptcy auction, expanding its rare disease portfolio.
Pulse 2.0 · +8 outlets
Sandoz and Shanghai Henlius Biotech enter strategic collaboration on up to 10 biosimilars
The deal expands Sandoz's biosimilar pipeline globally and gives Henlius access to international markets.
TradingView · +3 outlets
AbelZeta regains global rights for Prizlon-cel, gets FDA IND clearance for large B-cell lymphoma trial
The FDA clearance allows AbelZeta to advance its CAR-T therapy Prizlon-cel into clinical development for large B-cell lymphoma.
The Clinical Trial Vanguard · +1 outlets
FDA approves Vera Therapeutics' drug for rare kidney disease
Vera's stock surged on the FDA approval for its treatment targeting a rare kidney disease.
Stocktwits · +14 outlets
FDA approves MannKind's Afrezza for diabetes in children
The expanded FDA label opens a pediatric market for MannKind's inhaled insulin product Afrezza.
Stocktwits · +14 outlets
FDA approves AbbVie's drug for rare blood cancer
AbbVie received FDA approval for a treatment targeting a rare hematologic malignancy.
Stocktwits · +14 outlets
JW Pharmaceutical's Epaminurad shows statistical superiority in Phase III gout trial
The Phase III success positions Epaminurad as a potential new gout therapy that enhances uric acid excretion.
BioPharma APAC · +1 outlets
Vogenx IPO raises $81M for trial in metabolic disease with no approved drugs
The IPO proceeds will fund a clinical trial for a metabolic condition lacking any FDA-approved therapies.
medcitynews.com · +1 outlets
FDA rejects Grace Therapeutics' brain injury drug; shares plunge 45%
The FDA rejection sends shares down sharply, though the company says the concerns are fixable.
Stocktwits
OncoSil Medical secures FDA approval for OncoSil device for bile duct cancer
The FDA approval opens an estimated $80 million annual market in the US for the bile duct cancer device.
Proactive financial news · +8 outlets
Dimerix secures US IND for Phase 2-ready acute kidney injury drug DMX-652
The IND clearance allows Dimerix to advance its kidney injury drug into US clinical development.
Kalkine Media · +4 outlets
Mesoblast completes treatment in pivotal low back pain trial ahead of Phase 3 readout
Mesoblast's cell therapy for chronic low back pain has completed treatment, with Phase 3 results expected soon.
PharmaDispatch · +9 outlets
Skye Bioscience acquires Redx Pharma, exits obesity for fibrosis focus
Skye pivots away from obesity to concentrate on fibrosis, acquiring Redx Pharma in the process.
The Clinical Trial Vanguard · +1 outlets
Alto Neuroscience expands ALTO 207 program with new funding
The company is advancing its neuropsychiatry pipeline with a new funding round for ALTO 207.
simplywall.st · +13 outlets
AbCellera stock soars 64% following positive menopause drug trial
AbCellera shares surged on positive clinical data for a menopause-related drug candidate.
sekbernews.id
Ocugen targets 2027 BLA filings as gene therapy programs near key readouts
Ocugen is progressing its gene therapy pipeline toward regulatory submissions for 2027.
TradingView · +6 outlets